The US FDA Authorizes the Emergency Use of Antimalarial Drugs to Combat COVID-19

 The US FDA Authorizes the Emergency Use of Antimalarial Drugs to Combat COVID-19

The US FDA Authorizes the Emergency Use of Antimalarial Drugs to Combat COVID-19

Shots:

  • The US FDA has issued the EUA to the hydroxychloroquine and chloroquine products donated to the Strategic National Stockpile (SNS) to be distributed and utilized to treat patients with COVID-19
  • The SNS will distribute anti-malarial drugs to the states for doctors to prescribe it to adolescent and adult patients hospitalized with COVID-19 and who cannot be part of clinical studies
  • The SNS will work with FEMA for donating doses to the states. Additionally, the EUA requires fact sheets, providing information regarding the anti-malarial therapies in treating COVID-19 to be made available to HCPs and patients, including the risks and drug interactions associated with the drugs

Click here to­ read full press release/ article | Ref: FDA | Image: Pink Sheet

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post